Share-based Payment Arrangement, Expense of Karyopharm Therapeutics Inc. from 31 Dec 2011 to 31 Dec 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Karyopharm Therapeutics Inc. annual and quarterly Share-based Payment Arrangement, Expense in USD history and change rate from 31 Dec 2011 to 31 Dec 2025.
  • Karyopharm Therapeutics Inc. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $2,803,000, a 33% decline year-over-year.
  • Karyopharm Therapeutics Inc. annual Share-based Payment Arrangement, Expense for 2025 was $14,050,000, a 24% decline from 2024.
  • Karyopharm Therapeutics Inc. annual Share-based Payment Arrangement, Expense for 2024 was $18,426,000, a 15% decline from 2023.
  • Karyopharm Therapeutics Inc. annual Share-based Payment Arrangement, Expense for 2023 was $21,709,000, a 39% decline from 2022.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)

Karyopharm Therapeutics Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2025 $14,050,000 -$4,376,000 -24% 01 Jan 2025 31 Dec 2025 10-K 13 Feb 2026 2025 FY
2024 $18,426,000 -$3,283,000 -15% 01 Jan 2024 31 Dec 2024 10-K 13 Feb 2026 2025 FY
2023 $21,709,000 -$13,690,000 -39% 01 Jan 2023 31 Dec 2023 10-K 13 Feb 2026 2025 FY
2022 $35,399,000 +$5,616,000 +19% 01 Jan 2022 31 Dec 2022 10-K 19 Feb 2025 2024 FY
2021 $29,783,000 +$5,376,000 +22% 01 Jan 2021 31 Dec 2021 10-K 29 Feb 2024 2023 FY
2020 $24,407,000 +$9,116,000 +60% 01 Jan 2020 31 Dec 2020 10-K 17 Feb 2023 2022 FY
2019 $15,291,000 -$1,984,000 -11% 01 Jan 2019 31 Dec 2019 10-K 01 Mar 2022 2021 FY
2018 $17,275,000 -$3,130,000 -15% 01 Jan 2018 31 Dec 2018 10-K 24 Feb 2021 2020 FY
2017 $20,405,000 -$1,878,000 -8.4% 01 Jan 2017 31 Dec 2017 10-K 26 Feb 2020 2019 FY
2016 $22,283,000 +$5,226,000 +31% 01 Jan 2016 31 Dec 2016 10-K 28 Feb 2019 2018 FY
2015 $17,057,000 +$2,817,000 +20% 01 Jan 2015 31 Dec 2015 10-K 15 Mar 2018 2017 FY
2014 $14,240,000 +$10,455,000 +276% 01 Jan 2014 31 Dec 2014 10-K 16 Mar 2017 2016 FY
2013 $3,785,000 +$3,132,000 +480% 01 Jan 2013 31 Dec 2013 10-K 15 Mar 2016 2015 FY
2012 $653,000 +$629,000 +2621% 01 Jan 2012 31 Dec 2012 10-K 13 Mar 2015 2014 FY
2011 $24,000 01 Jan 2011 31 Dec 2011 10-K 21 Mar 2014 2013 FY

Karyopharm Therapeutics Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $2,803,000 -$1,379,000 -33% 01 Jul 2025 30 Sep 2025 10-Q 03 Nov 2025 2025 Q3
Q1 2025 $16,800,000 $3,784,000 -$1,626,000 -30% 01 Jan 2025 31 Mar 2025 10-Q 11 Aug 2025 2025 Q2
Q4 2024 $18,426,000 $3,424,000 -$1,758,000 -34% 01 Oct 2024 31 Dec 2024 10-K 13 Feb 2026 2025 FY
Q3 2024 $20,184,000 $4,182,000 -$896,000 -18% 01 Jul 2024 30 Sep 2024 10-Q 03 Nov 2025 2025 Q3
Q2 2024 $21,080,000 $5,410,000 -$650,000 -11% 01 Apr 2024 30 Jun 2024 10-Q 06 Aug 2024 2024 Q2
Q1 2024 $21,730,000 $5,410,000 +$21,000 +0.39% 01 Jan 2024 31 Mar 2024 10-Q 11 Aug 2025 2025 Q2
Q4 2023 $21,709,000 $5,182,000 -$991,000 -16% 01 Oct 2023 31 Dec 2023 10-K 13 Feb 2026 2025 FY
Q3 2023 $22,700,000 $5,078,000 -$1,719,000 -25% 01 Jul 2023 30 Sep 2023 10-Q 05 Nov 2024 2024 Q3
Q2 2023 $24,419,000 $6,060,000 -$9,033,000 -60% 01 Apr 2023 30 Jun 2023 10-Q 06 Aug 2024 2024 Q2
Q1 2023 $33,452,000 $5,389,000 -$1,947,000 -27% 01 Jan 2023 31 Mar 2023 10-Q 08 May 2024 2024 Q1
Q4 2022 $35,399,000 $6,173,000 -$696,000 -10% 01 Oct 2022 31 Dec 2022 10-K 19 Feb 2025 2024 FY
Q3 2022 $36,095,000 $6,797,000 -$623,000 -8.4% 01 Jul 2022 30 Sep 2022 10-Q 02 Nov 2023 2023 Q3
Q2 2022 $36,718,000 $15,093,000 +$6,958,000 +86% 01 Apr 2022 30 Jun 2022 10-Q 02 Aug 2023 2023 Q2
Q1 2022 $29,760,000 $7,336,000 -$23,000 -0.31% 01 Jan 2022 31 Mar 2022 10-Q 04 May 2023 2023 Q1
Q4 2021 $29,783,000 $6,869,000 +$555,000 +8.8% 01 Oct 2021 31 Dec 2021 10-K 29 Feb 2024 2023 FY
Q3 2021 $29,228,000 $7,420,000 +$907,000 +14% 01 Jul 2021 30 Sep 2021 10-Q 03 Nov 2022 2022 Q3
Q2 2021 $28,321,000 $8,135,000 +$1,707,000 +27% 01 Apr 2021 30 Jun 2021 10-Q 04 Aug 2022 2022 Q2
Q1 2021 $26,614,000 $7,359,000 +$2,207,000 +43% 01 Jan 2021 31 Mar 2021 10-Q 05 May 2022 2022 Q1
Q4 2020 $24,407,000 $6,314,000 +$2,765,000 +78% 01 Oct 2020 31 Dec 2020 10-K 17 Feb 2023 2022 FY
Q3 2020 $21,642,000 $6,513,000 +$2,794,000 +75% 01 Jul 2020 30 Sep 2020 10-Q 03 Nov 2021 2021 Q3
Q2 2020 $18,848,000 $6,428,000 +$2,312,000 +56% 01 Apr 2020 30 Jun 2020 10-Q 05 Aug 2021 2021 Q2
Q1 2020 $16,536,000 $5,152,000 +$1,245,000 +32% 01 Jan 2020 31 Mar 2020 10-Q 04 May 2021 2021 Q1
Q4 2019 $15,291,000 $3,549,000 01 Oct 2019 31 Dec 2019 10-K 01 Mar 2022 2021 FY
Q3 2019 $3,719,000 01 Jul 2019 30 Sep 2019 10-Q 02 Nov 2020 2020 Q3
Q2 2019 $4,116,000 01 Apr 2019 30 Jun 2019 10-Q 04 Aug 2020 2020 Q2
Q1 2019 $3,907,000 01 Jan 2019 31 Mar 2019 10-Q 05 May 2020 2020 Q1
Q3 2013 $1,323,000 +$1,167,000 +748% 01 Jul 2013 30 Sep 2013 10-Q/A 23 Dec 2013 2013 Q3
Q3 2012 $156,000 01 Jul 2012 30 Sep 2012 10-Q/A 23 Dec 2013 2013 Q3
* An asterisk sign (*) next to the value indicates that the value is likely invalid.